Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1756-1763

  Shigemasa, Kazushi ^a   Gu, Lijun ^a   O'Brien, Timothy J ^b   Ohama, Koso ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MESSENGER RNA; PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY ADENOCARCINOMA; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; S-PHASE KINASE-ASSOCIATED PROTEINS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0037989911     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. MacLachlan, T. K., Sang, N., and Giordano, A. Cyclins, cyclin- dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit. Rev. Eukaryotic Gene Expression, 5: 127-156, 1995.
2. Sherr, C. J. Cancer cell cycle. Science (Wash. DC), 274: 1672-1677, 1994.
3. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J. Clin., 46: 5-27, 1996.
4. Deshaies, R. J. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell Dev. Biol., 15: 435-467, 1999.
5. Patton, E. E., Willems, A. R., and Tyers, M. Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis. Trends Genet., 14: 236-243, 1998.
6. Kipreos, E. T., and Pagano, M. The F-box protein family. Genome Biol., 1: 3002.1-3002.7, 2000.
7. Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell, 82: 915-925, 1995.
8. Kip1, polyploidy and centrosome overduplication. EMBO J., 19: 2069-2081, 2000.
9. Carrano, A. C., Eytan, E., Hershko, A., and Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol., 1: 193-199, 1999.
10. Kip1 degradation and induces S phase in quiescent cells. Nat. Cell Biol., 1: 207-214, 1999.
11. Skp2 complex through phosphorylated Thr187 in p27. Curr. Biol., 9: 661- 664, 1999.
12. Reynisdottir, I., Polyak, K., Iavarone, A., and Massague, J. Kip/Cip and Ink4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev., 9: 1831-1845, 1995.
13. Kip1 and cyclin E. alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
14. Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
15. Kip1 and apoptosis in human breast cancer. Br. J. Cancer, 79: 1572-1578, 1999.
16. Sui, L., Tokuda, M., Ohno, M., Hatase, O., and Hando, T. The concurrent expression of p27 (kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol. Oncol., 73: 202-209, 1999.
17. Masciullo, V., Sgambato, A., Pacilio, C., Pucci, B., Ferrandina, G., Palazzo, J., Carbone, A., Cittadini, A., Mancuso, S., Scambia, G., and Giordano, A. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res., 59: 3790-3794, 1999.
18. Shigemasa, K., Shiroyama, Y., Sawasaki, T., Fujii, T., Nagai, N., Parmley, T. H., O'Brien, T. J., and Ohama, K. Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas. Int. J. Oncol., 18: 953-958, 2001.
19. Mori, M., Mimori, K., Shiraishi, T., Tanaka, S., Ueo, H., Sugima- chi, K., and Akiyoshi, T. p27 expression and gastric carcinoma. Nat. Med., 3: 593, 1997.
20. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
21. Kip1 protein in human prostate cancer correlates with tumor grade. Clin. Cancer Res., 3: 2269-2274, 1997.
22. Bamberger, A. M., Riethdorf, L., Milde, L. K., Bamberger, C. M., Thuneke, I., Erdmann, I., Schulte, H. M., and Loning, T. Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia. Virchows Arch., 434: 423-428, 1999.
23. Russel, P. Surface epithelial-stromal tumors of the ovary. In: R. J. Kurman (ed.), Blaustein's Pathology of the Female Genital Tract, pp. 705-782. New York: Springer-Verlag, 1995.
24. International Federation of Gynecology and Obstetrics (FIGO) Committee on Gynecologic Oncology, Benedet, J. L., Bender, H., Jones, H., III, Ngan, H. Y. S., and Pecorelli, S. FIGO staging classifications and clinical practice guidelines in the management of gynecological cancers. Int. J. Gynecol. Obstet., 70: 209-262, 2000.
25. Shigemasa, K., Hu, C., West, C. M., Clarke, J., Parham, G. P., Parmley, T. H., Korourian, S., Baker, V. V., and O'Brien, T. J. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J. Soc. Gynecol. Invest., 4: 95-102, 1997.
26. Shigemasa, K., Hu, C., West, C. M., Moon, S. H., Parham, G. P., Parmley, T. H., Korourian, S., Baker, V. V., and O'Brien, T. J. p21: a monitor of p53 dysfunction in ovarian neoplasia. Int. J. Gynecol. Cancer, 7: 296-303, 1997.
27. Shigemasa, K., Tanimoto, H., Parham, G. P., Parmley, T. H., Ohama, K., and O'Brien, T. J. Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J. Soc. Gynecol. Invest., 6: 102-108, 1999.
28. Shigemasa, K., Underwood, L. J., Beard, J., Tanimoto, H., Ohama, K., Parmley, T. H., and O'Brien, T. J. Overexpression of testisin, a serine protease expressed by testicular germ cells, in epithelial ovarian tumor cells. J. Soc. Gynecol. Invest., 7: 358-362, 2000.
29. Gstaiger, M., Jordam, R., Lim, M., Catzavelos, C., Mestan, J., Slingerland, J., and Krek, W. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl. Acad. Sci. USA, 98: 5043-5048, 2001.
30. Latres, E., Chiarle, R., Schulman, B. A., Pavletich, N. P., Pellicer, A., Inghirami, G., and Pagano, M. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl. Acad. Sci. USA, 98: 2515-2520, 2001.
31. Nelsen, C. J., Hansen, L. K., Rickheim, D. G., Chen, C., Stanley, M. W., Krek, W., and Albrecht, J. H. Induction of hepatocyte prolifer- ation and liver hyperplasia by the targeted expression of cyclin E and skp2. Oncogene, 20: 1825-1831, 2001.
32. Chao, Y., Shih, Y-L., Chiu, J-H., Chau, G-Y., Lui, W-Y., Yang, W. K., Lee, S-D., and Huang, T-S. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res., 58: 985-900, 1998.
33. Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcino- mas. Cancer (Phila.), 91: 1745-1751, 2001.
34. Kudo, Y., Kitajima, S., Sato, S., Miyauchi, M., Ogawa, I., and Takata, T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res., 61: 7044-7047, 2001.